bronchoscopy
Conditions
Interventions
Control group:Remifentanil 1 µg/kg plus Remimazolam 0.2 mg/kg
experimental group:Alfentanil 15 µg/kg plus Remimazolam 0.2 mg/kg
Sponsors
The Central Hospital of Wuhan
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients scheduled to undergo fiberoptic bronchoscopy under general anesthesia at our hospital, with an ASA classification of I-III; 2. Aged between 18 and 75 years (inclusive of 18 and 75); 3. No known history of allergy to relevant anesthetic medications; 4. No recent use of sedative or analgesic medications; 5. Patients and their families have been informed of and have consented to this study;
Exclusion criteria
Exclusion criteria: 1. Patients with respiratory failure (PaO2 50 mmHg); 2. Patients with NYHA Class IV cardiac function, severe arrhythmias, or structural heart disease; 3. Patients with acute cerebral infarction or cognitive/mental disorders; 4. Patients with Child-Pugh Class C liver function or chronic kidney disease (CKD) stages 4-5; 5. Patients with communication difficulties; 6. Patients with coagulation abnormalities; 7. Patients with a difficult airway; 8. Pregnant or lactating patients; 9. Participation in other clinical trials within the last 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| incidence of bronchospasm or laryngospasm;Cough Score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Airway pressure and pulmonary compliance during mechanical ventilation;Operator satisfaction score;Glottic opening visualized under bronchoscopy after induction;Postoperative extubation time;Incidence of adverse events;Incidence of intraoperative hypotension;Patient satisfaction score;Incidence of intraoperative hypoxemia; | — |
Countries
China
Contacts
Public ContactMu Xu
The Central Hospital of Wuhan
Outcome results
None listed